Medication-induced constipation: Clinical sciences

Last updated: June 08, 2026

Medication-induced constipation: Clinical sciences

Pharmacology

Pharmacology

Cell wall synthesis inhibitors: Penicillins
Cell wall synthesis inhibitors: Cephalosporins
Miscellaneous cell wall synthesis inhibitors
Miscellaneous protein synthesis inhibitors
Protein synthesis inhibitors: Aminoglycosides
Protein synthesis inhibitors: Tetracyclines
DNA synthesis inhibitors: Fluoroquinolones
DNA synthesis inhibitors: Metronidazole
Antimetabolites: Sulfonamides and trimethoprim
Herpesvirus medications
Neuraminidase inhibitors
Hepatitis medications
Nucleoside reverse transcriptase inhibitors (NRTIs)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Protease inhibitors
Integrase and entry inhibitors
Anthelmintic medications
Anti-mite and louse medications
Antimalarials
Azoles
Echinocandins
Miscellaneous antifungal medications
Antituberculosis medications
Anaphylaxis
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Thiazide and thiazide-like diuretics
Potassium sparing diuretics
Loop diuretics
Osmotic diuretics
Adrenergic antagonists: Alpha blockers
ACE inhibitors, ARBs and direct renin inhibitors
cGMP mediated smooth muscle vasodilators
Positive inotropic medications
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Anticoagulants: Heparin
Thrombolytics
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Antiplatelet medications
Mineralocorticoids and mineralocorticoid antagonists
Acid reducing medications
Glucocorticoids
Laxatives and cathartics
Medication-induced constipation: Clinical sciences
Inflammatory bowel disease: Pathology review
Pulmonary corticosteroids and mast cell inhibitors
Bronchodilators: Leukotriene antagonists and methylxanthines
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Approach to a cough (subacute and chronic): Clinical sciences
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Obesity and metabolic syndrome: Clinical sciences
Insulins
Osteoporosis medications
Hyperthyroidism medications
Hypothyroidism medications
Non-corticosteroid immunosuppressants and immunotherapies
Estrogens and antiestrogens
Androgens and antiandrogens
Opioid agonists, mixed agonist-antagonists and partial agonists
Non-steroidal anti-inflammatory drugs
Seizures and epilepsy
Local anesthetics
General anesthetics
Anticonvulsants and anxiolytics: Benzodiazepines
Anticonvulsants and anxiolytics: Barbiturates
Selective serotonin reuptake inhibitors
Atypical antidepressants
Tricyclic antidepressants
Lithium
Typical antipsychotics
Atypical antipsychotics
Anti-parkinson medications
Alzheimer disease: Clinical sciences
Allergic rhinitis: Clinical sciences
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Urinary incontinence: Pathology review
PDE5 inhibitors

Decision-Making Tree

Transcript

Watch video only

Medication-induced constipation refers to a decreased stooling frequency or difficulty passing stool due to medication side effects, most commonly opioids.

Opioids are medications that can bind mu receptors in the central nervous system, and provide analgesic effects, but they can also affect the gastrointestinal tract, eventually decreasing gastrointestinal motility. In severe cases, this can result in constipation.

Other important non-opioid medications that may cause constipation include anticholinergics, antidepressants, antispasmodics, and calcium channel blockers.

Now, if a patient presents with signs and symptoms suggestive of medication-induced constipation, you should first perform a focused history and physical examination.

Your patient might report decreased stooling, such as three or fewer bowel movements per week; as well as difficulty passing stools; firm stool consistency; or a sense of incomplete stool evacuation after defecation.

Additionally, history might reveal the use of medications like opioids, or non-opioid medications like anticholinergics, antidepressants, antispasmodics, or calcium channel blockers.

On physical examination, you’ll typically find mild to moderate abdominal distension, while rectal exam may reveal fecal impaction, hemorrhoids, anal fissures, or even rectal prolapse. Based on these findings, you should suspect medication-induced constipation.

Now here’s a clinical pearl to keep in mind! Whenever a patient presents with signs and symptoms of constipation, you’ll first need to rule out medical causes, like dehydration or hypothyroidism. Look for red-flag symptoms, like a history of unintentional weight loss or blood in the stool, as well as physical exam findings like significant abdominal distension or tenderness.

If any of these are present, evaluate for other causes of constipation, such as colon cancer or bowel obstruction. You will also want to make sure your patient is up-to-date on their colorectal cancer screening if indicated.

Now, once you suspect medication-induced constipation, review your patient’s medication list to identify the cause. If they have been taking an opioid for 7 or more days, and if constipation began or worsened after initiating the medication, you can diagnose opioid-induced constipation, or OIC for short.

Next, you should review the specific opioid and dose, and consider medication changes. This might include reducing the opioid to the minimum effective dose;

as well as opioid rotation or switching to a different opioid agent; or even switching to a non-opioid medication.

Next, encourage lifestyle modifications, like educating the patient to defecate immediately upon urge, optimizing dietary fiber and fluid intake, and increasing physical activity. In addition, start medical management with a scheduled combination of laxatives. For example, combine a stimulant laxative, such as senna or bisacodyl, with an osmotic laxative, like polyethylene glycol, which is more effective than either medication alone.

Now, here’s another clinical pearl! When you prescribe opioids to a patient, keep in mind that your patient will be at increased risk for OIC, so prophylactically prescribe a laxative with or without a stool softener, and educate your patient on lifestyle modifications.

Now that you’ve initiated the management, assess your patient’s response to treatment.

If your patient has an adequate response to treatment and their constipation improves, then continue current management.

On the other hand, if there’s inadequate response and their constipation persists, prescribe a peripherally-acting mu-opioid receptor antagonist, or PAMORA, such as naldemedine, naloxegol, or methylnaltrexone.

PAMORA medications block the activity of mu-opioid receptors in the intestines but not in the CNS, reducing the constipating effect of opioid medications without reducing their analgesic effects.

After one week, reassess your patient’s response to the prescribed PAMORA, and if constipation improves, continue current management.

Sources

  1. "Relationship Between Constipation and Medication" Journal of UOEH (2019)
  2. "Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel" Advances in Therapy (2021)
  3. "Chronic Constipation" Mayo Clinic Proceedings (2019)
  4. "Mechanisms, Evaluation, and Management of Chronic Constipation" Gastroenterology (2020)
  5. "Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis" Gut (2018)
  6. "Treatment of constipation in older adults" American family physician (2005)
  7. "American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation" Gastroenterology (2019)